- Home
- ANVS vs GNLX Comparison
ANVS vs GNLX Comparison
Compare ANVS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | GNLX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 124.8M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ANVS | GNLX |
|---|---|---|
| Price | $2.58 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.50 | ★ $19.75 |
| AVG Volume (30 Days) | ★ 306.0K | 135.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | 18.10 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $1.99 |
| 52 Week High | $5.50 | $8.54 |
Technical Indicators
Market Signals| Indicator | ANVS | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 49.36 |
| Support Level | $2.29 | $2.54 |
| Resistance Level | $2.98 | $2.80 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 42.36 | 46.08 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.